Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Jourdain, Hugo
39  Ergebnisse:
Personensuche X
?
1

Persistence and safety of anti-TNF biosimilars versus origi..:

Jourdain, Hugo ; Hoisnard, Léa ; Sbidian, Emilie.
RMD Open.  10 (2024)  1 - p. e003531 , 2024
Link: https://doi.org/10.1136/..
 
?
2

Severe Hypersensitivity Reactions at Biosimilar versus Orig..:

Jourdain, Hugo ; Hoisnard, Léa ; Sbidian, Emilie.
BioDrugs.  37 (2023)  3 - p. 397-407 , 2023
Link: https://doi.org/10.1007/..
 
?
3

Drug survival and safety of biosimilars and originator adal..:

Phan, Duc Binh ; Jourdain, Hugo ; González-Quesada, Alicia...
BMJ Open.  13 (2023)  7 - p. e075197 , 2023
Link: https://doi.org/10.1136/..
 
?
4

Roll-out and effectiveness of HIV pre-exposure prophylaxis ..:

Billioti de Gage, Sophie ; Jourdain, Hugo ; Desplas, David.
Therapies.  78 (2023)  5 - p. 585-591 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Real-world effectiveness of pre-exposure prophylaxis in men..:

Jourdain, Hugo ; de Gage, Sophie Billioti ; Desplas, David.
The Lancet Public Health.  7 (2022)  6 - p. e529-e536 , 2022
Link: https://doi.org/10.1016/..
 
?
6

TNF-alpha inhibitors biosimilar use in France: a nationwide..:

Jourdain, Hugo ; Hoisnard, Léa ; Sbidian, Emilie.
Scientific Reports.  12 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
7

Drug survival and safety of biosimilars and originator adal..:

Phan, Duc Binh ; Jourdain, Hugo ; González-Quesada, Alicia...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351260/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
8

TNF-alpha inhibitors biosimilar use in France: a nationwide..:

Jourdain, Hugo ; Hoisnard, Léa ; Sbidian, Emilie.
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-022-24050-7.  , 2022
Link: https://hal.u-pec.fr/hal..
 
?
9

TNF-alpha inhibitors biosimilar use in France: a nationwide..:

Jourdain, Hugo ; Hoisnard, Léa ; Sbidian, Emilie.
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-022-24050-7.  , 2022
Link: https://hal.u-pec.fr/hal..
 
?
10

TNF-alpha inhibitors biosimilar use in France: a nationwide..:

Jourdain, Hugo ; Hoisnard, Léa ; Sbidian, Emilie.
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-022-24050-7.  , 2022
Link: https://hal.u-pec.fr/hal..
 
?
11

TNF-alpha inhibitors biosimilar use in France: a nationwide..:

Jourdain, Hugo ; Hoisnard, Léa ; Sbidian, Emilie.
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-022-24050-7.  , 2022
Link: https://hal.u-pec.fr/hal..
 
?
12

Characteristics of patients aged 75 years and over recurren..:

Jourdain, Hugo
dumas-03735817.  , 2022
Link: https://dumas.ccsd.cnrs...
 
?
13

TNF-alpha inhibitors biosimilar use in France: a nationwide..:

Jourdain, Hugo ; Hoisnard, Léa ; Sbidian, Emilie.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666557/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
14

Drug survival and safety of biosimilars and originator adal..:

Mark Lunt ; R B Warren ; Zenas Z N Yiu...
https://bmjopen.bmj.com/content/13/7/e075197.full.  , 2023
Link: https://doi.org/10.1136/..
 
?
15

TNF-alpha inhibitors biosimilar use in France: a nationwide..:

Hugo Jourdain ; Léa Hoisnard ; Emilie Sbidian.
https://doi.org/10.1038/s41598-022-24050-7.  , 2022
Link: https://doi.org/10.1038/..
 
1-15